Scalability 2024

Advancing gene therapy development with a multi-serotype AAV affinity resin

Cell & Gene Therapy Insights 2024; 10(2), 237–253

DOI: 10.18609/cgti.2024.036

Published: 4 April
Innovator Insight
Nicolas Laroudie, Quentin Bazot

AAV purification poses a number of unique challenges to viral vector manufacturers including the need for scalability, a significant impurity burden, and ensuring a good recovery yield. In this article, a multi-serotype AAV affinity resin will be described and its use illustrated by relevant experiences and case studies from a CMDO developing an AAV purification platform for application across various AAV serotypes and client processes.